Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer 25 trials found
New Search
Filter
Trial Phase
Study Type
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
PHASE1INTERVENTIONAL Denver, Colorado +4 more
RECRUITING
Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer
NAINTERVENTIONAL Carcassonne +4 more
RECRUITING
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
PHASE1, PHASE2INTERVENTIONAL Duarte, California +4 more
RECRUITING
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
PHASE1INTERVENTIONAL Boston, Massachusetts +4 more
RECRUITING
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
N/AOBSERVATIONAL Gainesville, Florida +4 more
RECRUITING
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
PHASE2INTERVENTIONAL Miami, Florida +4 more
RECRUITING
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
N/AOBSERVATIONAL Karlsruhe, Baden-Wüttemberg +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
NAINTERVENTIONAL Milwaukee, Wisconsin +4 more
RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
PHASE1INTERVENTIONAL Boston, Massachusetts +4 more
RECRUITING
Study on Female Patients' Mammographic Texture Features
NAINTERVENTIONAL Tampere
RECRUITING
Planning Grant for TOPS for Breast Cancer Survivors
NAINTERVENTIONAL Durham, North Carolina
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
IDOV-Immune for Advanced Solid Tumors
PHASE1INTERVENTIONAL St Louis, Missouri +4 more
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
Distance-Based Exercise to Preserve Function and Prevent Disability
NAINTERVENTIONAL Dublin, California +4 more
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
PHASE1INTERVENTIONAL Grand Rapids, Michigan +4 more
RECRUITING
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
PHASE3INTERVENTIONAL Anderlecht, North Rhine-Westphalia +4 more
RECRUITING
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
PHASE4INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
PHASE2, PHASE3INTERVENTIONAL Québec, Quebec +4 more
RECRUITING
Clinical Study to Assess the Safety and Performance of Kenko Breast AI+ Medical Device as an Aid to Breast Cancer Diagnosis in Adult Women
N/AOBSERVATIONAL Elche, Alicante
RECRUITING
Filter Trials
Trial Phase
Study Type